Furthermore, whole transcriptome analysis comparing HR+HER2- early-stage BC from patients ≤50 vs >50 years from the FLEX trial found no substantial differences in gene expression in MammaPrint Low Risk, genomically luminal tumors. Here, ERBB2 is linked to breast cancer.